Evaluation and Long-Term Outcomes of Cardiac Toxicity in Paediatric Cancer Patients
Authors:
- Jake A. KleinmahonJKJake A. Kleinmahon
- Bruce F. LandeckBLBruce F. Landeck
- IiIIIi
Open Access
- 7 June 2017
- book chapter
- Published by IntechOpen
Abstract
Evaluation and Long-Term Outcomes of Cardiac Toxicity in Paediatric Cancer Patients | InTechOpen, Published on: 2017-06-07. Authors: Jake A. Kleinmahon and Bruce F. Landeck, IIKeywords
This publication has 33 references indexed in Scilit:
- Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and TrastuzumabCirculation: Cardiovascular Imaging, 2012
- Tissue Doppler and myocardial deformation imaging to detect myocardial dysfunction in pediatric cancer patients treated with high doses of anthracyclinesAsia-Pacific Journal of Clinical Oncology, 2012
- Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic OutcomesJournal of Clinical Oncology, 2012
- Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2010
- Anthracycline-Induced CardiomyopathyJACC, 2010
- B‐type natriuretic peptide as a marker for cardiac dysfunction in anthracycline‐treated childrenPediatric Blood & Cancer, 2006
- Cardiotoxicity of cytotoxic drugsCancer Treatment Reviews, 2004
- Enalapril to Prevent Cardiac Function Decline in Long-Term Survivors of Pediatric Cancer Exposed to AnthracyclinesJournal of Clinical Oncology, 2004
- Long-Term Prospective Follow-Up Study of Cardiac Function After Cardiotoxic Therapy for Malignancy in ChildrenJournal of Clinical Oncology, 2003
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialThe Lancet, 1999